ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
Molekulargewicht:
394.63
Reinheit:
98.63%
CAS Nummer:
[1638200-22-2]
Formel:
C11H9BrClN3O4S
Target-Kategorie:
TLR
T39115
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten